Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Randomization in Phase II Clinical Trials

Greg Yothers1, Samuel Wieand, Emil J Freireich

  • 1NSABP Biostatistical Center, Pittsburgh, PA, USA.

Clinical Advances in Hematology & Oncology : H&O
|November 23, 2006
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease.

Future oncology (London, England)·2026
Same author

The Care and Cure of the Leukemias in 2026.

American journal of hematology·2026
Same author

Analyses of adverse events and patient-reported outcomes with the toxicity index in cancer clinical trials.

Cancer·2025
Same author

The Definition of Cure in Colon Cancer: A Pooled Analysis of 15 Randomized Clinical Trials.

JAMA oncology·2025
Same author

Erratum: Machine Learning Predicts Oxaliplatin Benefit in Early Colon Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

NSABP FC-11: A phase II study of neratinib plus trastuzumab or neratinib plus cetuximab in patients with "quadruple wild-type" (KRAS/NRAS/BRAF/PIK3CA) metastatic colorectal cancer based on HER2 status: amplified, non-amplified (wild-type), or mutated.

Cancer chemotherapy and pharmacology·2025